Decentralized trials

For successful decentralized clinical trials, researchers must encourage patient engagement. Learn 5 steps that modern companies are taking for better outcomes.

Castor is shifting the research paradigm for eCRF in clinical trials, transitioning from old, inefficient processes to a comprehensive CDMS & DCT platform.

This white paper from Castor explores the importance of choosing an EDC with an API before starting a clinical trial.

This white paper from Castor explores the importance of choosing an EDC with an API before starting a clinical trial.

Leaders from Castor discuss what changes we can expect in clinical research, technology, and data through the lens of three key pillars

Each rare disease research breakthrough offers the promise of a longer, better life for patients who otherwise may…

Researchers are looking to incorporate remote technologies into medical device trials for a wide range of device classifications. This article explores current regulations for various classes of medical devices and how this will impact the need for participants to visit research sites throughout the trial.

The Castor team is thrilled to see an increasing emphasis on diversity of race, gender, and even geography amongst clinical trial participants. Critically, experts call for not just increased diversity on a statistical basis, but that the studied population is representative of the distribution of the disease.

DTx represent an emerging field of software-driven, evidence-based products intended to “prevent, manage, or treat a medical disease or disorder.” Cybersecurity is a concern for DTx, whether they are being evaluated through clinical research or are aiming at market release.

At Castor, we hope to see DCT extend into all trials as we work alongside researchers in the pursuit of the ultimate goal of democratized clinical research.